Robyn P. Araujo

Robyn P. Araujo

Auto-generated profile, based on publicly available information

Robyn P. Araujo

Affiliation School of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in Bulletin of Mathematical Biology
Verified
Journal Article
Closed access
RAR P Araujo
R P Araujo
DMD L S McElwain
D L S McElwain

9 November 2006 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
EPEmanuel F. Petricoin
Emanuel F. Petricoin
CBClaudio Belluco
Claudio Belluco
RARobyn P. Araujo
Robyn P. Araujo
LLLance A. Liotta
Lance A. Liotta

1 April 2005 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
KSKatherine M. Sheehan
Katherine M. Sheehan
VCValerie S. Calvert
Valerie S. Calvert
EKElaine W. Kay
Elaine W. Kay
YLYiling Lu
Yiling Lu
DFDavid Fishman
David Fishman
JWJulia D. Wulfkuhle
Julia D. Wulfkuhle
Cancer can be defined as a deregulation or hyperactivity in the ongoing network of intracellular and extracellular signaling events. Reverse phase protein microarray technology may offer a new opportunity to measure and profile these signaling pathways, providing data on post-translational phosphorylation events not obtainable by gene microarray analysis. Treatment of ovarian epithelial carcinoma almost always takes place in a metastatic setting since unfortunately the disease is often not detected until later stages. Thus, in addition to elucidation of the molecular network within a tumor specimen, critical questions are to what extent do signaling changes occur upon metastasis and are there common pathway elements that arise in the metastatic microenvironment. For individualized combinatorial therapy, ideal therapeutic selection based on proteomic mapping of phosphorylation end points may require evaluation of the patient’s metastatic tissue. Extending these findings to the bedside will require the development of optimized protocols and reference standards. We have developed a reference standard based on a mixture of phosphorylated peptides to begin to address this challenge.

1 April 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
EPEmanuel F. Petricoin
Emanuel F. Petricoin
VEVirginia Espina
Virginia Espina
RARobyn P. Araujo
Robyn P. Araujo
BMBrieanne Midura
Brieanne Midura
CYChoh Yeung
Choh Yeung
LLLance A. Liotta
Lance A. Liotta
Mapping of protein signaling networks within tumors can identify new targets for therapy and provide a means to stratify patients for individualized therapy. Despite advances in combination chemotherapy, the overall survival for childhood rhabdomyosarcoma remains ∼60%. A critical goal is to identify functionally important protein signaling defects associated with treatment failure for the 40% nonresponder cohort. Here, we show, by phosphoproteomic network analysis of microdissected tumor cells, that interlinked components of the Akt/mammalian target of rapamycin (mTOR) pathway exhibited increased levels of phosphorylation for tumors of patients with short-term survival. Specimens (n = 59) were obtained from the Children's Oncology Group Intergroup Rhabdomyosarcoma Study (IRS) IV, D9502 and D9803, with 12-year follow-up. High phosphorylation levels were associated with poor overall and poor disease-free survival: Akt Ser473 (overall survival P < 0.001, recurrence-free survival P < 0.0009), 4EBP1 Thr37/46 (overall survival P < 0.0110, recurrence-free survival P < 0.0106), eIF4G Ser1108 (overall survival P < 0.0017, recurrence-free survival P < 0.0072), and p70S6 Thr389 (overall survival P < 0.0085, recurrence-free survival P < 0.0296). Moreover, the findings support an altered interrelationship between the insulin receptor substrate (IRS-1) and Akt/mTOR pathway proteins (P < 0.0027) for tumors from patients with poor survival. The functional significance of this pathway was tested using CCI-779 in a mouse xenograft model. CCI-779 suppressed phosphorylation of mTOR downstream proteins and greatly reduced the growth of two different rhabdomyosarcoma (RD embryonal P = 0.00008; Rh30 alveolar P = 0.0002) cell lines compared with controls. These results suggest that phosphoprotein mapping of the Akt/mTOR pathway should be studied further as a means to select patients to receive mTOR/IRS pathway inhibitors before administration of chemotherapy. [Cancer Res 2007;67(7):3431–40]

1 October 2005 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
MLMark S. Lowenthal
Mark S. Lowenthal
AMArpita I Mehta
Arpita I Mehta
KFKristina Frogale
Kristina Frogale
RBRussell W. Bandle
Russell W. Bandle
RARobyn P. Araujo
Robyn P. Araujo
LLLance A Liotta
Lance A Liotta
Background: Albumin binds low–molecular-weight molecules, including proteins and peptides, which then acquire its longer half-life, thereby protecting the bound species from kidney clearance. We developed an experimental method to isolate albumin in its native state and to then identify [mass spectrometry (MS) sequencing] the corresponding bound low–molecular-weight molecules. We used this method to analyze pooled sera from a human disease study set (high-risk persons without cancer, n= 40; stage I ovarian cancer, n = 30; stage III ovarian cancer, n = 40) to demonstrate the feasibility of this approach as a discovery method. Methods: Albumin was isolated by solid-phase affinity capture under native binding and washing conditions. Captured albumin-associated proteins and peptides were separated by gel electrophoresis and subjected to iterative MS sequencing by microcapillary reversed-phase tandem MS. Selected albumin-bound protein fragments were confirmed in human sera by Western blotting and immunocompetition. Results: In total, 1208 individual protein sequences were predicted from all 3 pools. The predicted sequences were largely fragments derived from proteins with diverse biological functions. More than one third of these fragments were identified by multiple peptide sequences, and more than one half of the identified species were in vivo cleavage products of parent proteins. An estimated 700 serum peptides or proteins were predicted that had not been reported in previous serum databases. Several proteolytic fragments of larger molecules that may be cancer-related were confirmed immunologically in blood by Western blotting and peptide immunocompetition. BRCA2, a 390-kDa low-abundance nuclear protein linked to cancer susceptibility, was represented in sera as a series of specific fragments bound to albumin. Conclusion: Carrier-protein harvesting provides a rich source of candidate peptides and proteins with potential diverse tissue and cellular origins that may reflect important disease-related information.

1 November 2007 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
RARobyn P. Araujo
Robyn P. Araujo
LLLance A. Liotta
Lance A. Liotta
EPEmanuel F. Petricoin
Emanuel F. Petricoin